SKLB-178

antineoplastic; structure in first source

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

1.	Neoplasm Metastasis (Metastasis) 02/21/2017 - "The in vivo pharmacodynamic studies further demonstrated that SKLB-178 had wider potency than Gefitinib, and could significantly prolong survival of animals in A549 experimental metastasis model. "
2.	Neoplasms (Cancer) 02/21/2017 - "SKLB-178 potently inhibited cancer cell growth in both Gefitinib-sensitive and resistant NSCLC cells. "
3.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/21/2017 - "Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer."

1.	Gefitinib (Iressa)